CA Patent

CA2905172C — 177-lu labeled peptide for site-specific upar-targeting

Assigned to TRT Innovations ApS · Expires 2021-07-20 · 5y expired

What this patent protects

There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an…

USPTO Abstract

There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.

Drugs covered by this patent

Patent Metadata

Patent number: CA2905172C
Jurisdiction: CA
Classification: —
Expires: 2021-07-20
Drug substance claim: No
Drug product claim: No
Assignee: TRT Innovations ApS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.